[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oropharyngeal-carcinoma-opc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oropharyngeal-carcinoma-opc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652056","phase-3-a-randomized-multicentre-study-to-evaluate-crb-701-compared-to-investigators-choice-therapy-in-previously-treated-oropharyngeal-squamous-cell-carcinoma-100652056",false,"NCT07768189","A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma","A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor","TEMPO-1","Inclusion Criteria:\n\n* Histological and\u002For cytological confirmed diagnosis of OPSCC arising from tonsils, base of tongue, soft palate and posterior pharyngeal wall, with evidence of metastatic or recurrent disease not amenable to standard therapy with curative intent.\n* Either second or third-line OPSCC patients who have progressed on or after receiving SOC therapy (that must have included platinum chemotherapy and an anti-PD-(L)1 antibody administered sequentially or together) OR received platinum chemotherapy and\u002For anti-PD-(L)1 therapy in the neoadjuvant or adjuvant setting or as part of definitive chemoradiation therapy, provided disease recurrence occurred less than 6 months after completion of the relevant systemic therapy.\n* ECOG PS of 0-1\n* Measurable disease as per RECIST v1.1, with at least one measurable lesion not previously irradiated unless unequivocal progression has been documented after radiation.\n* Life expectancy of greater than 12 weeks at time of enrollment, as per Investigator's assessment.\n\nSigned informed consent\n\nExclusion Criteria:\n\n* Persistent CTCAE Grade \\>1 clinically significant toxicities related to prior antineoplastic therapies, excluding alopecia.\n* Significant active or chronic corneal disorders\n* Pre-existing Grade ≥2 peripheral neuropathy\n* Any other significant co-morbidities, disease, metabolic dysfunction, physical examination, or clinical laboratory finding that contraindicates the use of the investigational drug or may represent an unacceptable risk from treatment complications or may affect adherence to the study procedures or the interpretation of the results.\n* Pregnant or breastfeeding females","ALL","18 Years",{"count":20,"type":21},260,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum based chemotherapy or immunotherapy (using a check-point inhibitor) It will also learn about the safety of the drug and measure quality of life. The main questions it asks are:\n\n* What proportion of participants respond to CRB-701 measured using scans (CT or MRI)\n* What medical problems do participants experience when taking CRB-701.\n\nResearchers will compare CRB-701 with standard of care medicines (drugs that are normally used this disease).\n\nParticipants will:\n\n* Attend clinic every three weeks to receive infusions of CRB-701 or standard of care medicines until the cancer cannot be measured or is not controlled by the treatment they are receiving.\n* Have a CT or MRI every 6 weeks to measure the effect on their cancer\n* Complete questionnaires to assess their health status.",[27],"Oropharyngeal Carcinoma (OPC)",[29,30,31,32,33,34],"Antibody Drug Conjugate","Nectin-4","Oropharyngeal Squamous Cell Carcinoma","HPV-ve","HPV+ve","Head and Neck Squamous Cell Carcinoma","NOT_YET_RECRUITING","2026-08-18",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":21},"2026-09-20",{"date":43,"type":21},"2029-03",{"name":45,"class":46},"Corbus Pharmaceuticals Inc.","INDUSTRY",27,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100648304","hpv-associated-oropharyngeal-carcinoma-hpv-opc-100648304","NCT07718620","HPV-associated Oropharyngeal Carcinoma (HPV-OPC)","Validation of a New Method for Monitoring HPV Infection in Patients With Head and Neck Cancers","HPV-OPC","Inclusion Criteria:\n\n* a patient with an oropharyngeal tumor indicated for curative radiation therapy or chemoradiotherapy\n* if radiation therapy or chemoradiotherapy was preceded by surgery, the patient may be enrolled if the lesion persists on imaging studies\n* the lesion must be a histologically confirmed squamous cell carcinoma with known p16 status\n* age ≥ 18 years\n* the subject must be willing and able to provide written informed consent for specimen collection\n* ability to communicate effectively with the investigator in the local language, and ability to understand and comply with the study requirements\n\nExclusion Criteria:\n\n* previous induction chemotherapy\n* unknown p16 status, incomplete or inadequate histology-e.g., adenocarcinoma, melanoma, lymphoma,\n* previous radiation therapy to the oropharynx\n* palliative patients indicated for accelerated radiation therapy with a treatment duration of \\\u003C 5.5 weeks\n* age \\\u003C 18 years\n* pregnant or breastfeeding women\n* patients in the terminal stage of life\n* severe alcohol and\u002For drug abuse during treatment",{"count":57,"type":21},35,[59],"NA","This study focuses on the longitudinal monitoring of HPV infection in patients with head and neck cancers, particularly oropharyngeal carcinoma (OPC), using a new electrochemical detection method. This method has already been successfully developed and validated for cervical cancer. The aim of the project is to monitor the dynamics of HPV viral load before the start of treatment and during conservative radiation therapy or concurrent chemoradiation therapy. HPV will be analyzed from oral swabs, oral cavity washings, and plasma as part of a small prospective study. The results of the new method will be correlated with standard techniques, particularly qPCR. Longitudinal monitoring may contribute to the individualization and potential de-escalation of treatment in selected patients.",[27],[63],"HPV-positive head and neck tumors","RECRUITING","2026-07-17",{"date":67,"type":39},"2026-07-22",{"date":69,"type":39},"2026-05-25",{"date":71,"type":21},"2027-03",{"name":73,"class":74},"Masaryk Memorial Cancer Institute","OTHER",1]